APA (7th ed.) Citation

KO, M., S, K., GM, F., AJ, W., C, B., P, K., . . . H, B. (2022). TH-MYCN tumors, but not tumor-derived cell lines, are adrenergic lineage, GD2+, and responsive to anti-GD2 antibody therapy. Oncoimmunology, 11(1), 2075204. https://doi.org/10.1080/2162402X.2022.2075204

Chicago Style (17th ed.) Citation

KO, McNerney, et al. "TH-MYCN Tumors, but Not Tumor-derived Cell Lines, Are Adrenergic Lineage, GD2+, and Responsive to Anti-GD2 Antibody Therapy." Oncoimmunology 11, no. 1 (2022): 2075204. https://doi.org/10.1080/2162402X.2022.2075204.

MLA (9th ed.) Citation

KO, McNerney, et al. "TH-MYCN Tumors, but Not Tumor-derived Cell Lines, Are Adrenergic Lineage, GD2+, and Responsive to Anti-GD2 Antibody Therapy." Oncoimmunology, vol. 11, no. 1, 2022, p. 2075204, https://doi.org/10.1080/2162402X.2022.2075204.